Requires pharmacy benefits manager compensation to be based on bona fide service fee.
Summary
Assembly Bill 5019 would amend New Jersey law governing pharmacy benefits managers (PBMs) and how their compensation is treated for insurance rate and medical loss ratio purposes. The bill requires that compensation paid to a PBM, or to an affiliate of a PBM, for administering and managing prescription drug benefits be limited to a bona fide service fee rather than a commission structure or any other fee arrangement. The bill defines a bona fide service fee as a flat-dollar payment reflecting fair market value for an itemized service actually performed on behalf of the purchaser, and it must not be passed on to covered persons.
The bill also specifies that PBM compensation is to be treated as an administrative cost of the carrier, not as a benefit under the health benefits plan, and that carriers may count only amounts actually paid to pharmacies or pharmacists as incurred claims. In addition, rate filings for plans using PBMs must include actuarial documentation and supporting records regarding PBM compensation, and both carriers and PBMs must provide records needed to verify those calculations. The measure would apply to contracts and agreements entered into, renewed, modified, or amended on or after the effective date.
Impact
This bill would amend P.L.2023, c.107 and directly affect the regulation of health insurance carriers, pharmacy benefits managers, and pharmacy services administrative organizations in New Jersey. It would change how PBM compensation is structured and reported in rate filings, while giving the Department of Banking and Insurance authority to review calculations, request supporting documentation, and determine fair market value for bona fide service fees. The practical effect is to tighten oversight of PBM compensation and limit compensation methods tied to drug prices, rebates, formulary placement, or other performance-based arrangements.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and sponsor statement, the measure appears to be framed as a consumer- and transparency-oriented reform aimed at curbing opaque PBM compensation practices. The overall tone of the bill is regulatory and corrective rather than controversial in the text itself.
Contention
The main points of potential contention are likely to be the bill’s restriction on commission-based or contingent PBM compensation and the requirement that fees be limited to fair market value bona fide service fees set or recognized by the Commissioner of Banking and Insurance. PBMs and affiliated entities may object to limits on compensation structures, documentation requirements, and restrictions on fees tied to rebates, discounts, formulary decisions, or drug pricing metrics. Carriers and regulators may support the bill for increasing transparency and aligning compensation with actual services, while PBMs may argue it constrains contracting flexibility and could affect business arrangements and administrative costs.